Adenine Base Editor ABE7.10 Corrects Sickle Cell Disease HBB E6V Mutation in Patient-Derived Hematopoietic Stem Cells With >84% Editing Efficiency and Preserved Engraftment
These findings contribute empirically to hematology and genome editing and carry actionable implications for the design of programs and policies targeting SCD gene therapy clinical translation, base editing HSPC platform for hemoglobinopathies, and off-target safety framework for clinical-grade base editor development.